SK288052B6 - Polymorph 1 of bilastine, process for preparing thereof, its antihistaminic and antiallergic use and pharmaceutical preparation containing it - Google Patents

Polymorph 1 of bilastine, process for preparing thereof, its antihistaminic and antiallergic use and pharmaceutical preparation containing it Download PDF

Info

Publication number
SK288052B6
SK288052B6 SK5020-2004A SK50202004A SK288052B6 SK 288052 B6 SK288052 B6 SK 288052B6 SK 50202004 A SK50202004 A SK 50202004A SK 288052 B6 SK288052 B6 SK 288052B6
Authority
SK
Slovakia
Prior art keywords
bilastine
polymorph
antihistaminic
preparing
pharmaceutical preparation
Prior art date
Application number
SK5020-2004A
Other languages
English (en)
Slovak (sk)
Other versions
SK50202004A3 (sk
Inventor
Venero Aurelio Orjales
Martin Maravillas Bordell
Mori Gonzalo Canal
Fuente Haydee Blanco
De Pablo Maria Luisa Lucero
Royo Victor Rubio
Pestana Ramon Mosquera
Original Assignee
Faes Farma, S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29225789&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK288052(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Faes Farma, S.A. filed Critical Faes Farma, S.A.
Publication of SK50202004A3 publication Critical patent/SK50202004A3/sk
Publication of SK288052B6 publication Critical patent/SK288052B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SK5020-2004A 2002-04-19 2002-04-19 Polymorph 1 of bilastine, process for preparing thereof, its antihistaminic and antiallergic use and pharmaceutical preparation containing it SK288052B6 (sk)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/ES2002/000194 WO2003089425A1 (es) 2002-04-19 2002-04-19 POLIMORFO DEL ÁCIDO 4-[2-[4-[1-(2-ETOXIETIL)-1H-BENCIMIDAZOL-2-IL]-1-PIPERIDINIL]ETIL]-α, α-DIMETIL-BENCENOACÉTICO

Publications (2)

Publication Number Publication Date
SK50202004A3 SK50202004A3 (sk) 2005-05-05
SK288052B6 true SK288052B6 (sk) 2013-03-01

Family

ID=29225789

Family Applications (1)

Application Number Title Priority Date Filing Date
SK5020-2004A SK288052B6 (sk) 2002-04-19 2002-04-19 Polymorph 1 of bilastine, process for preparing thereof, its antihistaminic and antiallergic use and pharmaceutical preparation containing it

Country Status (31)

Country Link
US (2) US7612095B2 (bg)
EP (1) EP1505066B1 (bg)
JP (1) JP5142448B2 (bg)
KR (1) KR100673140B1 (bg)
CN (1) CN1290843C (bg)
AR (1) AR039423A1 (bg)
AT (1) ATE347550T1 (bg)
AU (1) AU2002255017B2 (bg)
BG (1) BG66302B1 (bg)
BR (1) BRPI0215703B8 (bg)
CA (1) CA2484460C (bg)
CY (2) CY1107564T1 (bg)
CZ (1) CZ305162B6 (bg)
DE (1) DE60216641T2 (bg)
DK (1) DK1505066T3 (bg)
ES (1) ES2278018T3 (bg)
HK (1) HK1072772A1 (bg)
HR (1) HRP20041048B1 (bg)
HU (1) HU230032B1 (bg)
IL (1) IL164645A (bg)
MX (1) MXPA04010313A (bg)
NO (1) NO329327B1 (bg)
NZ (1) NZ536551A (bg)
PA (1) PA8571201A1 (bg)
PE (1) PE20040086A1 (bg)
PT (1) PT1505066E (bg)
SI (1) SI1505066T1 (bg)
SK (1) SK288052B6 (bg)
UA (1) UA76866C2 (bg)
UY (1) UY27762A1 (bg)
WO (1) WO2003089425A1 (bg)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010013472A (ja) * 2009-09-09 2010-01-21 Faes Farma Sa ４−［２−［１−（２−エトキシエチル）−１Ｈ−ベンズイミダゾール−２−イル］−１−ピペリジニル］エチル］−α，α−ジメチルベンゼノ酢酸の多形体
US20140194111A1 (en) * 2011-06-30 2014-07-10 Panasonic Corporation Communication system, user terminal, and communication device
CN102675101B (zh) * 2012-05-16 2014-01-29 王蕾 2-(4-卤乙基)苯基-2-甲基丙酸酯的制备方法及合成比拉斯汀的方法
CZ307500B6 (cs) 2012-08-15 2018-10-24 Zentiva, K.S. Způsob přípravy derivátu 2-methyl-2´-fenylpropionové kyseliny využívající nové intermediáty
CN103214454A (zh) * 2013-03-30 2013-07-24 北京万全德众医药生物技术有限公司 一种比拉斯汀晶型及制备方法
WO2014188453A2 (en) * 2013-05-24 2014-11-27 Msn Laboratories Private Limited Novel process for the preparation of 2-[4-(2-{4-[1-(2-ethoxyethyl)-1h-benzimidazol-2-yl]-1-piperidinyl}ethyl) phenyl]-2-methylpropanoic acid
CN103356616A (zh) * 2013-06-29 2013-10-23 北京万全德众医药生物技术有限公司 一种含有比拉斯汀的药物组合物及其制备方法
CN104447682A (zh) * 2013-09-12 2015-03-25 天津市汉康医药生物技术有限公司 比拉斯汀化合物
CN104398481A (zh) * 2014-10-29 2015-03-11 万全万特制药江苏有限公司 比拉斯汀口崩片及其制备方法
CA2993134A1 (en) * 2015-07-24 2017-02-02 Urquima, S.A. Crystalline forms of bilastine and preparation methods thereof
EP3170816A1 (en) * 2015-11-20 2017-05-24 Faes Farma, S.A. Supersaturated compositions of benzimidazole compounds
EP3170817A1 (en) * 2015-11-20 2017-05-24 Faes Farma, S.A. Co-crystals of benzimidazole compounds
WO2017167949A1 (en) 2016-04-01 2017-10-05 Krka, D.D., Novo Mesto Crystalline forms of bilastine
EP3452462A4 (en) * 2016-05-05 2019-10-23 MSN Laboratories Private Limited, R&D Center SOLID STATE FORMS OF 2- [4- (2- {4- [1- (2-ETHOXYETHYL) -1H-BENZIMIDAZOL-2-YL] -1-PIPERIDINYL} ETHYL) PHENYL] -2-METHYLPROPANOIC ACID AND PREPARATION METHOD THEREOF
ES2813561T3 (es) 2017-09-07 2021-03-24 Tiefenbacher Alfred E Gmbh & Co Kg Composición farmacéutica en comprimido que comprende bilastina
ES2835287T3 (es) 2017-12-18 2021-06-22 Tiefenbacher Alfred E Gmbh & Co Kg Composición farmacéutica de comprimido que comprende la forma polimórfica 3 de bilastina y aluminometasilicato de magnesio
PL3641735T3 (pl) 2017-12-18 2021-09-06 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Kompozycja farmaceutyczna tabletki zawierająca bilastynę w postaci 3 i rozpuszczalny w wodzie wypełniacz
CA3088740A1 (en) 2018-01-18 2019-07-25 Faes Farma, S.A. Ophthalmic compositions comprising bilastine, a beta-cyclodextrin and at least one gelling agent
CA3200779A1 (en) 2020-12-23 2022-06-30 Strusi ORAZIO LUCA A non-micronized bilastine composition

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810789A (en) * 1987-08-28 1989-03-07 Bristol-Myers Company Process for buspirone hydrochloride polymorphic crystalline form conversion
ES2124167B1 (es) * 1996-06-04 1999-09-16 Espanola Prod Quimicos Nuevos derivados del bencimidazol con actividad antihistaminica.
BR0010683A (pt) * 1999-04-16 2003-07-01 Reddy Research Foundation Formas polimórficas de um agente antidiabético: processo para seu preparo e composições farmacêuticas contendo o mesmo
PE20010044A1 (es) * 1999-04-23 2001-03-10 Smithkline Beecham Plc Polimorfo de sal del acido maleico de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]-tiazolidina-2,4-diona

Also Published As

Publication number Publication date
BRPI0215703B8 (pt) 2021-05-25
DE60216641T2 (de) 2007-09-27
KR100673140B1 (ko) 2007-01-22
UY27762A1 (es) 2003-09-30
DK1505066T3 (da) 2007-03-19
ATE347550T1 (de) 2006-12-15
PE20040086A1 (es) 2004-04-27
BR0215703A (pt) 2005-02-01
BG66302B1 (bg) 2013-03-29
EP1505066B1 (en) 2006-12-06
JP5142448B2 (ja) 2013-02-13
ES2278018T3 (es) 2007-08-01
CY2013015I2 (el) 2015-08-05
EP1505066A1 (en) 2005-02-09
JP2005529120A (ja) 2005-09-29
HK1072772A1 (en) 2005-09-09
US20050203141A1 (en) 2005-09-15
CA2484460C (en) 2009-09-29
CZ305162B6 (cs) 2015-05-27
PA8571201A1 (es) 2003-12-10
HRP20041048B1 (hr) 2013-04-30
BRPI0215703B1 (pt) 2017-06-27
US7612095B2 (en) 2009-11-03
WO2003089425A1 (es) 2003-10-30
NZ536551A (en) 2006-08-31
NO329327B1 (no) 2010-09-27
HRP20041048A9 (hr) 2013-01-31
NO20044999L (no) 2005-01-14
DE60216641D1 (de) 2007-01-18
AU2002255017A1 (en) 2003-11-03
US20100004285A1 (en) 2010-01-07
BG108941A (bg) 2005-12-30
AR039423A1 (es) 2005-02-16
CZ20041122A3 (cs) 2005-03-16
HRP20041048A2 (en) 2005-02-28
MXPA04010313A (es) 2005-06-08
CN1290843C (zh) 2006-12-20
KR20050005448A (ko) 2005-01-13
HU230032B1 (hu) 2015-05-28
CY2013015I1 (el) 2015-08-05
CA2484460A1 (en) 2003-10-30
AU2002255017B2 (en) 2008-11-13
HUP0500241A2 (hu) 2005-06-28
SI1505066T1 (sl) 2007-04-30
IL164645A0 (en) 2005-12-18
CY1107564T1 (el) 2013-03-13
IL164645A (en) 2010-11-30
SK50202004A3 (sk) 2005-05-05
UA76866C2 (uk) 2006-09-15
CN1628112A (zh) 2005-06-15
PT1505066E (pt) 2007-03-30

Similar Documents

Publication Publication Date Title
SK288052B6 (sk) Polymorph 1 of bilastine, process for preparing thereof, its antihistaminic and antiallergic use and pharmaceutical preparation containing it
EP1513826B1 (en) New indolylpiperidine derivatives as potent antihistaminic and antiallergic agents
KR100626109B1 (ko) 항진균성 결정성 다형체 및 이를 포함하는 약제학적 조성물
KR20090048364A (ko) 아고멜라틴의 결정형 ⅵ, 이의 제조 방법 및 이를 함유하는약제학적 조성물
EP0579681B1 (en) Crystalline tiagabine hydrochloride monohydrate, its preparation and use
DE69922594T2 (de) Indazol-Derivate als 5-HT1F agonists
EP0517221B1 (en) [(Arylalkylpiperidine-4-yl)methyl]-2-alpha,3,4,5-tetrahydro-1(2H)-acenaphthylene-1-ones and related compounds, a process for their preparation and their use as medicaments
DE602004004378T2 (de) Verbindungen mit einer 5-ht2c rezeptor-wirkung und ihre verwendung
RU2288917C2 (ru) Полиморф 4-[2-[4-[1-(2-этоксиэтил)-1h-бензимидазол-2-ил]-1-пиперидинил]этил]-альфа, альфа-диметилбензолуксусной кислоты, способ его получения, фармацевтический препарат на его основе и его применение
JP2010013472A (ja) ４−［２−［１−（２−エトキシエチル）−１Ｈ−ベンズイミダゾール−２−イル］−１−ピペリジニル］エチル］−α，α−ジメチルベンゼノ酢酸の多形体
JPH0739415B2 (ja) ピロリジン誘導体
KR100494448B1 (ko) 항히스타민활성을가지는신규한벤조이미다졸유도체
PL205568B1 (pl) Polimorf 1 bilastyny, sposoby jego wytwarzania, preparaty farmaceutyczne go zawierające oraz jego zastosowanie
JPH08208640A (ja) ベンズイミダゾール誘導体およびそれを含有する心不全治療薬
JPH01113383A (ja) ２，４−ジアミノ−（ｅ）−６−［２−（３−ピリジル）エテニル］−１，３，５−トリアジンおよび該化合物を有効成分とする抗潰瘍剤
CZ12566U1 (cs) Amlodipinhemimaleát a farmaceutický prostředek

Legal Events

Date Code Title Description
SPCF Filing of an spc

Free format text: PRODUCT NAME: BILASTIN; NAT. REGISTRATION NO/DATE: 24/0912/10-S 20110125; FIRST REGISTRATION: IS IS/1/10/002/01 20100923

Spc suppl protection certif: 5007-2013

Filing date: 20130410

SPCG Grant of an spc

Free format text: PRODUCT NAME: BILASTIN; NAT. REGISTRATION NO/DATE: 24/0912/10-S 20110125; FIRST REGISTRATION: IS IS/1/10/002/01 20100923

Spc suppl protection certif: 166 5007-2013

Filing date: 20130410

Extension date: 20250923

MK4A Patent expired

Expiry date: 20220419